ArticleThe Journal of clinical investigation2001
The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation.
Article in The Journal of clinical investigation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 274 citations in OpenAlex.
- Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.The Journal of clinical investigation · 2012 · on this mapTrial
- Selective magnetic particle imaging of CD44 expressing cells using iron oxide nanoprobes functionalized with chemically modified hyaluronan.Nanoscale advances · 2026Article
- A rare pre-existing progenitor-like Primed SMC compartment is the dominant inferred source of SMC-derived cellularity in vascular injury and atherosclerosis.bioRxiv : the preprint server for biology · 2026Article
- ERG preserves endothelial identity to limit atherosclerosis.Nature communications · 2026Article
- Single-cell RNA sequencing reveals immune-peritubular myoid cell crosstalk driving testicular interstitial fibrosis in idiopathic non-obstructive azoospermia.Cell & bioscience · 2026Article
- Integrative genetic and expression profiling prioritizesFrontiers in immunology · 2026Article
- Plaque-Targeted Delivery of Fluoride-Free MXene Nanozyme for Alleviating Atherosclerosis via Sonocatalytic Therapy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- In Vivo Behavior of Biomimetic Nanoparticles: Strategies for Clearance Avoidance, Targeting, and Functional Delivery.Molecules (Basel, Switzerland) · 2025Review
- Article
- Expression of CD44 and Its Spliced Variants: Innate and Inducible Roles in Nervous Tissue Cells and Their Environment.International journal of molecular sciences · 2025Review
- Engineering Mechanical Microenvironments: Integration of Substrate and Flow Mechanics Reveals the Impact on the Endothelial Glycocalyx.ACS biomaterials science & engineering · 2025Article
- Molecular landscape of atherosclerotic plaque progression: insights from proteomics, single-cell transcriptomics and genomics.BMC medicine · 2025Article
- Inflammatory Transformation of Skin Basal Cells as a Key Driver of Cutaneous Aging.International journal of molecular sciences · 2025Article
- CD44 as a novel therapeutic target in pulmonary arterial hypertension: Insights from multi-omics integration and molecular docking.PloS one · 2025Article
- Lactylation-related geneFrontiers in immunology · 2025Article
- Integrated Single-Cell Analysis Revealed Novel Subpopulations of Foamy Macrophages in Human Atherosclerotic Plaques.Biomolecules · 2024Article
- Research progress on the therapeutic effects of nanoparticles loaded with drugs against atherosclerosis.Cardiovascular drugs and therapy · 2024Review
- CD44 signaling in Müller cells impacts photoreceptor function and survival in healthy and diseased retinas.Journal of neuroinflammation · 2024Article
- Research on the Mechanism and Material Basis of Corn (Pharmaceuticals (Basel, Switzerland) · 2024Review
- Hyaluronidase inhibitor delphinidin inhibits cancer metastasis.Scientific reports · 2024Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Atherosclerosis causes most acute coronary syndromes and strokes. The pathogenesis of atherosclerosis includes recruitment of inflammatory cells to the vessel wall and activation of vascular cells. CD44 is an adhesion protein expressed on inflammatory and vascular cells. CD44 supports the adhesion of activated lymphocytes to endothelium and smooth muscle cells. Furthermore, ligation of CD44 induces activation of both inflammatory and vascular cells. To assess the potential contribution of CD44 to atherosclerosis, we bred CD44-null mice to atherosclerosis-prone apoE-deficient mice. We found a 50-70% reduction in aortic lesions in CD44-null mice compared with CD44 heterozygote and wild-type littermates. We demonstrate that CD44 promotes the recruitment of macrophages to atherosclerotic lesions. Furthermore, we show that CD44 is required for phenotypic dedifferentiation of medial smooth muscle cells to the "synthetic" state as measured by expression of VCAM-1. Finally, we demonstrate that hyaluronan, the principal ligand for CD44, is upregulated in atherosclerotic lesions of apoE-deficient mice and that the low-molecular-weight proinflammatory forms of hyaluronan stimulate VCAM-1 expression and proliferation of cultured primary aortic smooth muscle cells, whereas high-molecular-weight forms of hyaluronan inhibit smooth muscle cell proliferation. We conclude that CD44 plays a critical role in the progression of atherosclerosis through multiple mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.